SRF Q4 Results FY26: PAT Rs 582 Crore Up 11 Percent, Indore BOPP Project Deferred

SRF Q4 results FY26 reported consolidated profit after tax of Rs 582 crore for the quarter ended March 31, 2026, up 11 percent year on year from Rs 526 crore in Q4 FY25. SRF Q4 results revenue from operations grew 7 percent year on year to Rs 4,615 crore, with the Chemicals business remaining the primary earnings driver while Packaging Films and Technical Textiles faced ongoing competitive pressure from Chinese imports.

The SRF Q4 results were accompanied by a significant capital allocation update: the board decided to defer the planned Rs 490 crore BOPP (biaxially oriented polypropylene) film manufacturing plant at Indore indefinitely, citing changed market conditions with excess global BOPP capacity depressing margins. SRF Q4 results EBITDA stood at Rs 1,026 crore with EBITDA margin of 22.2 percent, maintaining healthy profitability across the diversified conglomerate structure.

Get Free Stock Recommendations on Univest

SRF Q4 FY26 Results at a Glance

Track live SRF financials, analyst ratings and peer comparisons on the Univest Screener.

Key Highlights from SRF Q4 results

Chemicals Business Remains Core Profit Engine in SRF Q4 Results

SRF Q4 results PAT of Rs 582 crore is primarily driven by the Specialty Chemicals and Fluorochemicals segments, which collectively contribute the bulk of SRF’s consolidated EBITDA. The fluorochemical refrigerant business, which includes HFCs and next-generation HFO refrigerants, benefits from a global phase-out of older refrigerants driving structural volume growth. SRF Q4 results specialty chemical revenue from agro, pharma, and other specialty segments also grew on the back of India’s China plus one diversification trend in chemical sourcing. EBITDA margin of 22.2 percent in SRF Q4 results reflects the premium profitability of the chemicals segment.

Indore BOPP Project Deferral is Key Capital Allocation Signal in SRF Q4 Results

The SRF Q4 results board decision to indefinitely defer the Rs 490 crore Indore BOPP film plant reflects management’s disciplined capital allocation approach. Global BOPP film capacity has surged in recent years, particularly from China, depressing margins across the industry. The SRF Q4 results decision to avoid incremental investment in a structurally oversupplied segment protects return on capital. Instead, SRF Q4 results management signalled continued prioritisation of capex toward the higher-margin Specialty Chemicals and Fluorochemicals segments.

What Drove SRF Q4 FY26 Performance

SRF Q4 results performance was driven by Specialty Chemicals and Fluorochemicals segment growth, which benefited from volume expansion in HFO refrigerants, pharmaceutical chemistry active ingredients, and agrochemical intermediates. The China plus one supply chain diversification trend continues to drive SRF Q4 results export order wins in specialty chemical segments. Packaging Films and Technical Textiles remained under margin pressure from Chinese competition, but the chemicals mix improvement lifted consolidated SRF Q4 results EBITDA margin to 22.2 percent.

Outlook for FY27

Following SRF Q4 results, FY27 outlook is constructive for the Chemicals segment with HFO refrigerant phase-in driving volume growth, specialty chemical export order momentum continuing, and new fluoropolymer product launches. The Packaging Films segment remains a headwind in SRF Q4 results trajectory, but the deferral of the Indore BOPP project limits capital misallocation risk. Analyst targets for SRF post Q4 results range between Rs 3,200 and Rs 4,000.

Conclusion

SRF Q4 results FY26 confirm 11 percent PAT growth to Rs 582 crore, revenue of Rs 4,615 crore up 7 percent, and disciplined capital allocation with the Indore project deferral. SRF Q4 results confirm the Chemicals segment as the primary earnings engine for FY27. Track live SRF Q4 results data on the Univest Screener.

Download the Univest iOS App or Univest Android App for live SRF Q4 results tracking and expert research.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.

Frequently Asked Questions

What was the SRF Q4 results FY26 net profit?

SRF Q4 results FY26 reported consolidated PAT of Rs 582 crore, up 11 percent year on year from Rs 526 crore in Q4 FY25. Revenue grew 7 percent to Rs 4,615 crore with EBITDA of Rs 1,026 crore at 22.2 percent margin.

Why did SRF defer the Indore project in Q4 results FY26?

SRF Q4 results board deferred the Rs 490 crore Indore BOPP film plant indefinitely due to excess global BOPP capacity from China depressing industry margins. This reflects disciplined capital allocation away from structurally oversupplied segments toward Chemicals.

What drives SRF Q4 results profitability?

SRF Q4 results profitability is driven by Specialty Chemicals and Fluorochemicals including HFO refrigerants, agro-intermediates, and pharma chemistry, which maintain EBITDA margins well above 25 percent and benefit from China plus one sourcing trends.

What is the outlook after SRF Q4 results FY26?

Following SRF Q4 results, FY27 outlook is positive for Chemicals with HFO refrigerant phase-in and specialty export growth. Analyst targets range Rs 3,200 to Rs 4,000 for SRF post Q4 results.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026